ATyr Pharma To Present Preclinical Research Demonstrating Anti-Fibrotic Effects Of ATYR0101 In Lung and Kidney Fibrosis At Keystone Symposia On Fibrosis
ATyr Pharma To Present Preclinical Research Demonstrating Anti-Fibrotic Effects Of ATYR0101 In Lung and Kidney Fibrosis At Keystone Symposia On Fibrosis
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8 – 11, 2024, in Whistler, British Columbia, Canada.
aTyr製藥公司（納斯達克：ATYR）（「aTyr」或「公司」）是一家臨床階段的生物技術公司，專注於從其專有的tRNA合成酶平台發現和開發一流的藥物。今天宣佈，公司將在2024年12月8日至11日在加拿大不列顛哥倫比亞省惠斯勒舉行的纖維化：炎症、驅動因素和治療解決方案的基石研討會上展示與其tRNA合成酶候選藥物ATYR0101相關的兩個海報。
ATYR0101 is a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase (DARS) that binds to latent transforming growth factor beta binding protein 1 (LTBP-1) to induce myofibroblast apoptosis.
ATYR0101是一種融合蛋白，來源於專有的天冬氨酸-tRNA合成酶（DARS）的細胞外結構域，它能夠與潛在的轉化生長因子β結合蛋白1（LTBP-1）結合，以誘導肌纖維母細胞凋亡。